Adam S. Grossman

Adam S. Grossman files as President and CEO of Adma Biologics, Inc., the only company in the record, through 115 filings covering trades dated May 3, 2016 to March 16, 2026. The open-market side holds 17 purchases worth EUR 3,113,965 (median EUR 84,782) and 31 sales worth EUR 18,774,662 (median EUR 205,674). Purchases make up 35% of the market trades.

The largest purchase is dated May 3, 2016 (EUR 1,130,038). The two largest sales sit one day apart in August 2024: EUR 3,753,874 on August 26 and EUR 6,023,386 on August 27. Grants number 39 and option exercises 26.

Volume grew over time, from 1 filing in 2016 to 22 in 2024 and 36 in 2025. Over the last twelve months there are 20 filings, 10 of them sales and none a purchase. Within 30 days of colleagues at Adma Biologics, Inc., Grossman has 23, 20 and 12 own market trades, in that order. Same direction: 20, 20 and 12. The colleagues, in the same order: Jerrold B. Grossman, Brian Lenz and Lawrence P. Guiheen.

For the 17 purchases, the stored median 90-day result is -13.6%, with 35% of results positive (stored past results, not a forecast).